MacroGenics
Biopharmaceutical company focused on discovery, preclinical development, and early clinical development of monoclonal antibody–based therapeutics for oncology. Maintains integrated capabilities in protein engineering (including Fc-domain optimization), preclinical pharmacology and translational studies, biomarker assay development, and in‑house GMP biologics manufacturing and contract development/manufacturing services.
Industries
Nr. of Employees
small (1-50)
MacroGenics
9704 Medical Center Drive, Rockville, MD 20850
Patents
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US-11942149-B2
View Details
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US-11942149-B2
View DetailsProducts
Pipeline of engineered antibody therapeutics for oncology
Portfolio of investigational antibody candidates including Fc‑engineered antibodies, bispecific immune‑engaging constructs, and antibody–drug conjugates under preclinical and early clinical development for solid tumors and hematologic malignancies.
Pipeline of engineered antibody therapeutics for oncology
Portfolio of investigational antibody candidates including Fc‑engineered antibodies, bispecific immune‑engaging constructs, and antibody–drug conjugates under preclinical and early clinical development for solid tumors and hematologic malignancies.
Services
On-site services spanning antibody engineering, preclinical testing, process development, analytical testing, and GMP manufacture of clinical biologics provided as contract development and manufacturing services.
On-site services spanning antibody engineering, preclinical testing, process development, analytical testing, and GMP manufacture of clinical biologics provided as contract development and manufacturing services.
Expertise Areas
- Monoclonal antibody therapeutics for oncology
- Protein and antibody engineering (including Fc optimization and multispecific formats)
- Bispecific and T-cell engager development
- Antibody–drug conjugate discovery and preclinical development
Key Technologies
- Surface plasmon resonance for binding kinetics
- Antigen-capture immunoassays (ELISA)
- Multiparameter flow cytometry
- Cell-based ADCC and cytotoxicity assays
News & Updates
Corporate financial results and company progress update.
Announcement of planned participation in a healthcare industry conference.
Announcement of milestone payments received from a partner related to development progress of a PD‑1 inhibitor program and expected impact on corporate cash runway.
Announcement of milestone payment following partner nomination of a bispecific research program leveraging the company's bispecific platforms.
Announcement of board appointments, including committee assignments and expected contribution of scientific and strategic expertise.
Announcement of release date for first quarter 2024 financial results and accompanying conference call information.
Corporate financial results and company progress update.
Announcement of planned participation in a healthcare industry conference.
Announcement of milestone payments received from a partner related to development progress of a PD‑1 inhibitor program and expected impact on corporate cash runway.
Announcement of milestone payment following partner nomination of a bispecific research program leveraging the company's bispecific platforms.
Announcement of board appointments, including committee assignments and expected contribution of scientific and strategic expertise.
Announcement of release date for first quarter 2024 financial results and accompanying conference call information.